



Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

October 12, 2026

Conference Call and Webcast Scheduled for Monday, November 2

SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on November 2, 2026.



The schedule for the press release and conference call / webcast is as follows:

- Q3 2026 Press Release: November 2, 2026 at 1:00 p.m. PT / 4:00 p.m. ET
- Q3 2026 Conference Call: November 2, 2026 at 1:30 p.m. PT / 4:30 p.m. ET
- Domestic Dial-In Number: 800-347-6865
- International Dial-In Number: 203-518-9757
- Conference ID: NBIX

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on [LinkedIn](#), [X](#), [Facebook](#) and [YouTube](#). (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia: <https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2026-financial-results-302906096.html>

SOURCE Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.: Liz Reynolds (Media), 818-749-8778, media@neurocrine.com; Todd Tushla (Investors), 858-617-7143, ir@neurocrine.com